B+
Bull case
25%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
GNLX
GeneluxANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
A favorable controlled Phase 3 result could materially improve Olvi-Vec's regulatory prospects. Lung-cancer dose-finding data could add optionality, but the reported single-patient response is not proof of broader efficacy.
Posture
Constructive
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-11-02.
What can break
Binary Phase 3 efficacy, safety and regulatory risk in platinum-resistant or refractory ovarian cancer.
Momentum
20
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.30 · Bull $6.00 · Bear $0.70Analysis 2026-10-22; returns require an exact persisted reference.
Earnings
2026-11-02
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-22 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $18.83
Why
Momentum20 · Δ7d -
Value41 · Δ7d -0.0
Sentiment100 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-11-02.
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Binary Phase 3 efficacy, safety and regulatory risk in platinum-resistant or refractory ovarian cancer.
- • Cash runway reported only into Q1 2027; financing may dilute existing holders.
- • An unfavorable or delayed Phase 3 readout could sharply impair the thesis.
Catalyst clock
2026-11-02
Phase 3 OnPrime ovarian-cancer topline results
Lead driver: Sentiment · See AI snapshot
Momentum
20
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
100
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 20.0 / Value 40.6 / Sentiment 100.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-22. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$2.30
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.70
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$90.49M
Beta
-
Shares Out
45.25M
P/E (TTM) · Derived
-2.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.86
Rev YoY
-100.0%
EPS YoY
+7.2%
Gross Margin
-5925.0%
Op Margin
-391575.0%
Net Debt
-$12.91M
Current Ratio
2.39
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data